BeiGene Financials
| BGNE Stock | USD 190.30 0.21 0.11% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.77 | 2.3222 |
|
|
Investors should never underestimate BeiGene's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BeiGene's cash flow, debt, and profitability to make informed and accurate decisions about investing in BeiGene.
Net Income |
|
BeiGene | Select Account or Indicator |
Understanding current and past BeiGene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BeiGene's financial statements are interrelated, with each one affecting the others. For example, an increase in BeiGene's assets may result in an increase in income on the income statement.
BeiGene Earnings Geography
Please note, the presentation of BeiGene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BeiGene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BeiGene's management manipulating its earnings.
BeiGene Stock Summary
BeiGene competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Beigene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8600 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US07725L1026 |
| CUSIP | 07725L102 |
| Location | Cayman Islands |
| Business Address | 94 Solaris Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.beigene.com |
| Phone | 345 949 4123 |
| Currency | USD - US Dollar |
BeiGene Key Financial Ratios
| Return On Equity | -0.23 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.14) % | ||||
| Price To Sales | 0.90 X | ||||
| Revenue | 2.46 B |
BeiGene Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.6B | 5.6B | 8.6B | 6.4B | 5.8B | 3.2B | |
| Other Current Liab | 152.7M | 445.7M | 705.6M | 538.8M | 739.8M | 776.8M | |
| Other Liab | 57.1M | 443.3M | 562.5M | 283.7M | 326.3M | 342.6M | |
| Net Tangible Assets | 956.3M | 3.9B | 6.2B | 4.3B | 5.0B | 5.2B | |
| Net Debt | (340.7M) | (820.0M) | (3.7B) | (3.0B) | (2.2B) | (2.1B) | |
| Retained Earnings | (2.0B) | (3.6B) | (5.0B) | (7.1B) | (8.0B) | (7.6B) | |
| Accounts Payable | 122.5M | 232.0M | 168.0M | 294.8M | 315.1M | 330.9M | |
| Cash | 618.0M | 1.4B | 4.4B | 3.9B | 3.2B | 3.3B | |
| Other Assets | 108.7M | 186.8M | 8.6B | 819.9M | 2.0 | 1.9 | |
| Long Term Debt | 240.7M | 183.6M | 202.1M | 209.1M | 197.6M | 143.1M | |
| Other Current Assets | 85.8M | 141.0M | 253.1M | 288.2M | 205.5M | 111.8M | |
| Total Liab | 633.9M | 1.7B | 2.4B | 2.0B | 2.3B | 2.4B | |
| Total Current Assets | 1.2B | 5.0B | 7.6B | 4.7B | 4.2B | 2.6B | |
| Short Term Debt | 10.8M | 362.8M | 471.4M | 377.1M | 732.3M | 768.9M | |
| Common Stock | 79K | 118K | 133K | 135K | 155.3K | 83.2K | |
| Long Term Debt Total | 189.7M | 240.7M | 183.6M | 202.1M | 232.4M | 156.4M | |
| Capital Surpluse | 2.7B | 2.9B | 7.4B | 11.2B | 12.9B | 13.5B | |
| Net Receivables | 72.8M | 79.7M | 500.2M | 173.2M | 395.9M | 415.7M | |
| Inventory | 28.6M | 89.3M | 242.6M | 282.3M | 416.1M | 436.9M |
BeiGene Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 9.1M | 338K | 15.8M | 52.5M | 37.4M | 39.2M | |
| Total Revenue | 428.2M | 308.9M | 1.2B | 1.4B | 2.5B | 2.6B | |
| Gross Profit | (570.3M) | (1.1B) | (447.9M) | (511.1M) | 2.1B | 2.2B | |
| Operating Income | (959.9M) | (1.7B) | (1.4B) | (1.8B) | (1.2B) | (1.1B) | |
| Ebit | (959.9M) | (1.7B) | (1.4B) | (1.8B) | (1.2B) | (1.2B) | |
| Research Development | 927.3M | 1.3B | 1.5B | 1.6B | 1.8B | 1.7B | |
| Ebitda | (958.6M) | (1.6B) | (1.4B) | (1.7B) | (1.1B) | (1.2B) | |
| Cost Of Revenue | 998.5M | 1.4B | 1.6B | 1.9B | 379.9M | 746.8M | |
| Income Before Tax | (943.6M) | (1.6B) | (1.4B) | (2.0B) | (825.8M) | (867.1M) | |
| Net Income | (950.6M) | (1.6B) | (1.4B) | (2.0B) | (881.7M) | (925.8M) | |
| Income Tax Expense | 7.0M | (17.7M) | (25.2M) | 42.8M | 55.9M | 58.7M | |
| Tax Provision | 7.0M | (17.7M) | (25.2M) | 42.8M | 53.5M | 56.1M | |
| Net Interest Income | 9.1M | 2.0M | (15.8M) | 52.5M | 76.0M | 79.8M |
BeiGene Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 712.8M | (2.9B) | 955.5M | 1.1B | 161.1M | 169.2M | |
| Change In Cash | (119.9M) | 769.2M | 3.0B | (507.9M) | (689.1M) | (654.6M) | |
| Net Borrowings | 34.7M | 289.6M | 101.5M | (65.9M) | (75.8M) | (72.0M) | |
| Free Cash Flow | (908.9M) | (1.5B) | (1.6B) | (2.0B) | (1.7B) | (1.7B) | |
| Depreciation | 18.6M | 31.8M | 46.5M | 66.3M | 87.7M | 92.1M | |
| Other Non Cash Items | 67.6M | (21.0M) | (13.1M) | 3.3M | (361.2M) | (343.1M) | |
| Capital Expenditures | 158.6M | 229.0M | 314.9M | 469.1M | 581.3M | 610.3M | |
| Net Income | (950.6M) | (1.6B) | (1.4B) | (2.0B) | (881.7M) | (925.8M) | |
| End Period Cash Flow | 620.8M | 1.4B | 4.4B | 3.9B | 3.2B | 3.3B | |
| Change To Netincome | 184.5M | 248.7M | 186.5M | 308.5M | 354.8M | 372.5M | |
| Change To Inventory | (12.3M) | (58.9M) | (153.3M) | (56.7M) | (140.9M) | (133.9M) | |
| Change Receivables | (3.9M) | (29.8M) | 10.4M | (423.0M) | (380.7M) | (361.7M) |
BeiGene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BeiGene's current stock value. Our valuation model uses many indicators to compare BeiGene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BeiGene competition to find correlations between indicators driving BeiGene's intrinsic value. More Info.BeiGene is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At present, BeiGene's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value BeiGene by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BeiGene Systematic Risk
BeiGene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BeiGene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on BeiGene correlated with the market. If Beta is less than 0 BeiGene generally moves in the opposite direction as compared to the market. If BeiGene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BeiGene is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BeiGene is generally in the same direction as the market. If Beta > 1 BeiGene moves generally in the same direction as, but more than the movement of the benchmark.
BeiGene Thematic Clasifications
BeiGene is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
| Cancer Fighters | View |
Today, most investors in BeiGene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BeiGene's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BeiGene growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
BeiGene November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BeiGene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BeiGene. We use our internally-developed statistical techniques to arrive at the intrinsic value of BeiGene based on widely used predictive technical indicators. In general, we focus on analyzing BeiGene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BeiGene's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 13.85 | |||
| Value At Risk | (4.40) | |||
| Potential Upside | 3.46 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |